← Leaderboards
Thomas Preston Kennedy
Glycomira, Llc
$609,145
Attributed
$2,099,946
Total exposure
6
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $927.6K · FY2009–14$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$2,099,946 · 6
By mechanism
R44$1,190,122 · 1
R43$909,824 · 5
Top collaborators
- Glenn D Prestwich5 shared
- Narayanam Venkateswara Rao3 shared
- Justin Rodney Savage3 shared
- Paul J Shami3 shared
- Gregory John Johnson2 shared
- Balamurali K Ambati1 shared
- Ying Gu1 shared
- Siam Oottamasathien1 shared
Most similar at Glycomira, Llc
Same institution · by research overlap
- Narayanam Venkateswara Rao$124,938
- Justin Rodney Savage$2,775,433
- Jianxing Zhang$35,000
- Alana L Welm$9,642,442
- Won Yong Lee$2,853,952
Others in their field
Top investigators on “Pre-Clinical”
- Leonard Freedman · Leidos Biomedical Research, Inc.$264,541,531
- Dennis R. Burton · Scripps Research Institute$257,157,696
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barton F Haynes · Duke University$186,001,832
- David Heimbrook · Leidos Biomedical Research, Inc.$151,740,590
- Reisa A. Sperling · Banner Health$137,047,788
Research focus
Pre-ClinicalIn VivoChronicLeadInvestigational New Drug ApplicationPharmaceutical PreparationsAnimalsFamilyDoseDrug FormulationsSafetySmall Business Innovation Research GrantInjection Of Therapeutic AgentHyaluronic AcidAdvanced Glycosylation End ProductsChemistryHeparinPolysaccharidesInorganic SulfatesAnti-Inflammatory AgentsComplementBaseClinical TrialsGlycosaminoglycans
Grant awards (8)
Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer$142,814
R44 · FY2014 · CA
Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer$927,566
R44 · FY2012 · CA
Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis$210,000
R43 · FY2011 · DE
Novel Glycosaminoglycan Ethers for Prevention of Metastasis$210,000
R43 · FY2011 · CA
Novel Glycosaminoglycan Derivatives for Treatment of Bladder Inflammation$200,024
R43 · FY2011 · DK
Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer$119,742
R44 · FY2010 · CA
Sulfated Polysaccharide Derivatives for the Treatment of Rosacea$149,800
R43 · FY2009 · AR
Sulfated Polysaccharide Derivatives for Treatment of Macular Degeneration$140,000
R43 · FY2009 · EY